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Overexpression of SOX2 Is Associated with Better Overall Survival in
Squamous Cell Lung Cancer Patients Treated with 
Adjuvant Radiotherapy
Original Article
Purpose
The purpose of this study is to investigate the prognostic significance of SOX2 gene ampli-
fication and expression in patients with American Joint Committee on Cancer stage III lung
squamous cell carcinoma (SCC) who underwent surgery followed by adjuvant radiotherapy.
Materials and Methods
Pathological specimens were obtained from 33 patients with stage III lung SCC treated with
surgery followed by adjuvant radiotherapy between 1996 and 2008. SOX2 gene amplifica-
tion and protein expression were analyzed using fluorescent in situ hybridization and 
immunohistochemistry, respectively. Patients were divided into two groups according to
their SOX2 gene amplification and protein expression status. Kaplan-Meier estimates and
a Cox proportional hazards model were used to identify the prognostic factors affecting 
patient survival.
Results
The median follow-up period for surviving patients was 58 months (range, 5 to 102 months).
SOX2 gene amplification was observed in 22 patients and protein overexpression in 26 
patients. SOX2 overexpression showed significant association with SOX2 gene amplification
(p=0.002). In multivariate analysis, SOX2 overexpression was a significant prognostic factor
for overall survival (OS) (hazard ratios [HR], 0.1; 95% confidence interval [CI], 0.002 to 0.5;
p=0.005) and disease-free survival (DFS) (HR, 0.15; 95% CI, 0.04 to 0.65; p=0.01). Age
(HR, 0.33; 95% CI, 0.11 to 0.98; p=0.046) and total radiation dose (HR, 0.13; 95% CI, 0.02
to 0.7; p=0.02) were the independent prognostic factors for OS and DFS. Patients with
SOX2 amplification did not show a longer OS (p=0.95) and DFS (p=0.48).
Conclusion
Our data suggested that SOX2 overexpression could be used as a positive prognostic factor
in patients with stage III lung SCC receiving adjuvant radiotherapy.
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Introduction
Lung cancer has one of the highest cancer mortality rates
in several countries worldwide, including Korea [1,2]. 
Although cancer treatments have improved in recent
decades, lung cancer remains non-responsive to curative
treatments. However, novel emerging molecular techniques
have made it possible to investigate its molecular-level
pathophysiology, identify specific causative oncogenes or
tumor suppressor genes, and make progress toward new
paradigms for cancer treatment. Compared with other can-
cers, lung cancer has an increased number of well-defined
genetic changes and/or abnormalities and more molecularly
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targeted agents have been applied in clinical practice for its
treatment. However, most of the molecularly targeted agents
used in clinical practice are for adenocarcinoma, and few are
available for squamous cell carcinoma.
SOX2, a transcription factor encoded by the gene located
at 3q26.33, plays a role in maintenance of embryonic stem
cells. In addition, it is a “Yamanaka factor” which induces
pluripotent stem cells from somatic cells, along with c-Myc,
Oct4, and KLF4. It is also involved in morphogenesis and
homeostasis of the esophageal, tracheobronchial, and bron-
chiolar epithelium [3].
SOX2 is expressed in bronchial epithelial cells, though not
in alveolar cells or adenocarcinoma precursor lesions [4-6].
SOX2 is found exclusively in squamous cell carcinoma,
where it is amplified and overexpressed at the gene and pro-
tein levels, respectively [3,6]. Previous studies have analyzed
the prognosis of heterogeneously treated squamous cell car-
cinoma patient populations. However, only a small number
of studies have investigated the association between SOX2
and the clinical outcome of patients treated with radiother-
apy [7,8]. The aim of this study was to assess the prognostic
significance of SOX2 amplification and expression in squa-
mous cell lung cancer patients treated using adjuvant radio-
therapy.
Materials and Methods
1. Patient selection
This retrospective study was approved by the Institutional
Review Board of our institution (IRB No. 4-2012-0709). A
total of 158 non-small cell lung cancer (NSCLC) patients who
underwent pulmonary resection followed by adjuvant radio-
therapy between 1996 and 2008 were identified. Squamous
cell carcinoma was confirmed surgically in 71 patients, and
clinical specimens were available from 36 patients. Of these,
three patients were excluded from the analysis because of a
lack of tumor tissue in their paraffin-embedded tissue blocks.
Therefore, tumor samples from 33 patients were available for
analysis. The patients’ medical records were reviewed retro-
spectively for evaluation of clinicopathological characteris-
tics and survival outcomes. After radical resection, all
patients were determined to have pathologic TNM stage III
tumors according to the sixth edition cancer staging guide-
lines provided by the American Joint Committee on Cancer
[9]. 
2. Fluorescent in situ hybridization 
Fluorescent in situ hybridization (FISH) was performed for
analysis of SOX2 gene amplifications on 4-!m-thick forma-
lin-fixed paraffin embedded (FFPE) tissue sections. Briefly,
the sections were deparaffinized in xylene (twice for 10 min-
utes each), followed by immersion in 100% ethanol (twice for
5 minutes each) before hybridization. Pretreatment was per-
formed according to the Vysis protocol for FFPE tissue spec-
imens. A SOX2-specific DNA probe (green) and a centrom-
ere 3-specific probe (red) were used (ZytoLight SPEC SOX-
2/CEN 3 Dual Color Probe, ZytoVision, Bremerhaven, Ger-
many). The sections were then denatured and hybridized
with ThermoBrite (Abbott Molecular, Des Plaines, IL) at 80°C
for 5 minutes, followed by an overnight at 37°C. Post-hybr-
idization washes were performed according to the Vysis pro-
tocol for FFPE tissue specimens (Abbott Molecular), and
DAPI counterstaining was then performed. Semi-quantita-
tive analysis of the SOX2 amplification status was performed
by comparing the number of green signals (SOX2 target 
regions) to the number of red signals in each sample (refer-
ence regions). A non-amplified nucleus showed one green
target signal for every corresponding red reference signal,
with a green/red ratio of 1:1 (Fig. 1A). Cases containing 2-9
more green target signals than red signals in at least 30% of
their tumor cells were defined as having low-level SOX2
amplification (Fig. 1B). Cases with an additional ! 10 green
signals in a cluster-like formation were defined as having
high-level SOX2 amplification (Fig. 1C). All tissue slides
were analyzed under a 100" oil immersion objective lens
using a fluorescence microscope equipped with the appro-
priate filters. At least 100 nuclei per case were assessed. 
3. Immunohistochemistry
Four-micrometer-thick tissue sections were deparaffinized,
rehydrated, and washed twice in buffer. The slides were 
incubated in hydrogen peroxide for 10 minutes to reduce
nonspecific background staining due to endogenous perox-
idases, and then washed four times in buffer. Primary anti-
bodies against human SOX2 (1:200, R&D Systems, Minnea-
polis, MN) were then applied, and slides were incubated 
according to the manufacturer’s recommended protocols.
The slides were washed four times in buffer, incubated with
primary antibody enhancer for 20 minutes at room temper-
ature, and then washed four times in buffer. Next, horserad-
ish peroxidase polymer was applied to the slides, which were
then incubated for 30 minutes at room temperature before
washing four times in buffer, followed by incubation with
hematoxylin and chromogen, washed four times in deion-
ized water, and counterstained. The staining results were
evaluated and each case was scored from 0 to 2, according to
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the intensity of nuclear staining in the tumor cells. The stain-
ing intensity of the normal bronchial epithelium served as
the internal control and was given an arbitrary score of 1.
Each tumor was compared to the internal control and given
a score of 1 (moderate expression) (Fig. 1D) when the inten-
sity was the same as that of the internal control, 2 (strong 
expression) (Fig. 1E) when stronger, and 0 (weak expression)
(Fig. 1F) when weaker. 
4. Statistical analyses
Disease-free survival (DFS) was estimated from the time
of diagnosis to the time of initial tumor relapse (local recur-
rence or distant) or death from any cause. Overall survival
(OS) time was measured from the time of diagnosis to death
or last follow-up date. For univariate analysis, Kaplan-Meier
survival analyses were used to estimate OS and DFS, and dif-
ferences in the survival rates were compared using log-rank
tests. A Cox proportional hazards model was used for mul-
tivariate analysis to evaluate prognostic factors influencing
OS and DFS. Multivariate analysis was performed using
backwards elimination to stay in the model. Hazard ratios
(HR) are given with 95% confidence intervals (95% CI). Cor-
relations between categorical variables were examined using
!2 or Fisher exact tests. Continuous variables were compared
to categorical variables using Mann-Whitney U tests. Statis-
tical significance was defined as a p-value of < 0.05 for all
analyses. SPSS ver. 20.0 (IBM Co., Armonk, NY) was utilized
for all statistical analyses.
Results
1. Patient characteristics 
The median patient age was 66 years (range, 48 to 73
A
D
B
E
C
F
Fig. 1.  SOX2 amplification was assessed using fluorescence in situ hybridization (FISH, "1,000)  and protein expression was
determined using immunohistochemistry ("200) in lung squamous cell carcinoma patients. SOX2-specific DNA probe in
green combined with a centromere 3-specific probe in red was applied for FISH. (A) Nucleus without SOX2 amplification.
(B) Nucleus with low-level SOX2 amplification (arrows). (C) Nucleus with high-level SOX2 amplification (arrows). (D) Mod-
erate nuclear SOX2 expression (arrow). (E) Strong nuclear SOX2 expression (arrow). (F) Weak nuclear SOX2 expression.
Cancer Res Treat. 2016;48(2):473-482
476 CANCER  RESEARCH  AND  TREATMENT
years), and 32 patients were male (97%). Most patients had
an Eastern Cooperative Oncology Group (ECOG) perform-
ance status of 0 or 1 (93.9%) and a positive smoking history
(75.8%). Fourteen patients (42.4%) were classified as T3 or
T4, and 27 patients (81.8%) as N2 or N3. A positive margin
of resection was found in 11 patients (33.3%), lymphovascu-
lar invasion and perineural invasion in seven patients
(21.2%) and three patients (9.1%), and extranodal extension
in four patients (12.1%). The median total dose and fraction
size of radiotherapy were 59.4 Gy (range, 50.4 to 69 Gy) and
1.8 Gy (range, 1.8 to 2 Gy), respectively. The patient charac-
teristics are listed in Table 1.
2. Correlation between SOX2 gene amplification and pro-
tein expression and clinicopathological characteristics
SOX2 amplification was assessed using FISH and protein
expression was determined using immunohistochemistry in
lung squamous cell carcinoma patients (Fig. 1). High- and
low-level amplification were observed in four (12.2%) and 18
patients (54.5%), respectively (Table 1). SOX2 gene amplifi-
cation group was defined as low or high level amplification.
Strong and moderate expressions were observed in eight
(24.3%) and 18 patients (54.5%), respectively (Table 1). SOX2
overexpression was defined as a score of 1 or 2, and no over-
expression was defined as a score of 0.
Analysis of the correlation between SOX2 gene amplifica-
tion and protein expression showed significant association
of SOX2 overexpression with SOX2 gene amplification
(p=0.002) (Table 2). Next, we analyzed the association betw-
een several clinicopathological characteristics and SOX2 gene
amplification and protein expression. However, no clinico-
pathological factor showed significant association with SOX2
gene amplification or protein expression (Table 3).
3. Prognostic factors for OS and DFS
The median follow-up period for the surviving patients
was 58 months (range, 5 to 102 months). The 5-year OS and
DFS for all patients was 50.7% and 39.9%, respectively. In
prognostic analysis using Kaplan-Meier curves, SOX2 over-
expression was the only significant prognostic factor for OS
(yes vs. no; median, 73 months vs. 8 months; p=0.01) (Table 4).
Kaplan-Meier curves also showed that patients with SOX2
overexpression had significantly better OS, as shown in 
Fig. 2A. Age and total dose showed better OS with a statisti-
cally significant trend. However, SOX2 amplification did not
show association with OS (Table 4, Fig. 2B). In multivariate
analysis, SOX2 overexpression (HR, 0.1; 95% CI, 0.02 to 0.5;
p=0.005) and age (HR, 0.33; 95% CI, 0.11 to 0.98; p=0.046)
were the independent prognostic factors for OS (Table 4). In
univariate analysis, age (< 65 vs. ! 65; median, 96 months vs.
12 months; p=0.02) and total radiation dose (> 59.4 Gy vs. 
# 59.4 Gy; median, 96 months vs. 30 months; p=0.04) were
the significant prognostic factors for DFS (Table 4). SOX2
overexpression showed a significant trend toward better DFS
(p=0.08) (Table 4, Fig. 2C). SOX2 amplification also did not
show association with DFS (Table 4, Fig. 2D). In multivariate
analysis, SOX2 overexpression (HR, 0.15; 95% CI, 0.04 to 0.65;
p=0.01) and total radiation dose (HR, 0.13; 95% CI, 0.02 to 0.7;
p=0.02) were the independent prognostic factors for DFS
(Table 4).
Discussion
SOX2 plays roles in a variety of pathological processes
from normal development to cancer. Overexpression of 
SOX2 is not associated with epithelial cell differentiation in
the lungs, but its expression shows a notable increase in basal
cell precursors (p63+ Krt14$ cells) [10]. Therefore, SOX2 reg-
ulates the balance between self-renewal and differentiation
by controlling the fate of basal cells and also triggers lung
epithelial carcinogenesis [11].
SOX2 play a role in various signal transduction pathways
and exerts various biological effects via extensive networks
involving upstream and downstream molecules and protein
interactions [12]. Many proteins upstream of SOX2 have been
identified. EGFR-Src-Akt signaling is relevant to the self-
renewal of cancer stem cells and has an effect on side popu-
lation cells in lung cancer [13]. Several downstream effectors
of SOX2 have been identified including those involved in
cancer stem cell-related signal transduction pathways. For
example, C-MYC, WNT1, WNT2, and NOTCH1 play roles
in non-small cell lung cancer cells [14]. SOX2 was linked with
apoptosis in non-small cell lung cancer via the MAPK4-sur-
vivin pathway [15]. SOX2 forms a network with cell cycle
regulators including cyclin D1, cyclin E, and p27, as well as
other biologically important pathways such as "-catenin and
transforming growth factor " [16-18].
Little is known about the relationship between radioresis-
tance and SOX2. An analysis of the SOX2 interactome using
immunoprecipitation coupled with mass spectrometry
analysis by Fang et al. [19] found interactions between SOX2
and proteins involved in DNA repair, such as XRCC1, 5, and
6, which were associated with radioresistance in vitro and in
human tissues [20-22]. Future studies are needed to investi-
gate the direct relationship between radioresistance and
these genes. In addition, cancer stem cell radioresistance can
be explained by an increased recovery from DNA damage
and a decrease in production of reactive oxygen species
[23,24]. Therefore, SOX2 might influence radioresistance
Hong In Yoon, SOX2 Overexpression and Radiotherapy
VOLUME 48  NUMBER 2  APRIL  2016 477
through regulation of cancer stem cell activity. If SOX2 
increases radioresistance, SOX2 overexpression would result
in worse prognosis in irradiated patients, in contrast to our
findings. However, all patients enrolled in our study under-
went surgery followed by postoperative radiotherapy, and
most patients received adjuvant systemic chemotherapy.
Thus, we concluded that our findings were not appropriate
for investigating the relation between SOX2 and radioresis-
tance. Instead, we suggest that further studies designed for
decisive examination of this point, such as a prospective
study with lung squamous cell carcinoma patients who 
receive definitive radiotherapy, are required. 
Several previous studies investigated whether SOX2 amp-
lification was associated with prognosis in non-small cell
lung cancer. Although some reported that SOX2 amplifica-
tion showed close correlation with poor prognosis, others 
reported that patients with amplification had a good survival
outcome. These conflicting results arise from the limited
availability of patient tissues and methods for investigation
of SOX2 amplification. However, our findings showed that
SOX2 amplification is not associated with survival. 
A meta-analysis utilizing the eight published series found
significantly greater expression of SOX2 in squamous carci-
noma than in adenocarcinoma, which was associated with
improved OS. Similarly, multivariate analysis also showed
that SOX2 overexpression is the significant prognostic factor
for OS and DFS. Therefore, we suggest that overexpression
of SOX2 might be a positive prognostic factor in patients with
lung squamous cell carcinoma. However, as several studies
showed that the use of small interfering RNA to knockdown
SOX2 decreased the growth and radioresistance of cancer
cells in contrast to clinical studies [18,25], it remains unclear
whether this could result in a feasible therapeutic approach.
Therefore, further studies involving well-designed transla-
tional research from benchside to bedside are needed.
The current study included a homogenous NSCLC patient
population treated with adjuvant radiotherapy. To the best
of our knowledge, this is the first study to investigate whe-
ther SOX2 overexpression has prognostic significance in 
Table 1. Patient characteristics
Variable No. (%)
Age, median (range, yr) 66 (48-73)
Tumor size, median (range, cm) 4 (2-7)
Sex
Male 32 (97)
Female 1 (3)
ECOG
0 25 (75.7)
1 6 (18.2)
2 2 (6.1)
Smoking history
No 8 (24.2)
Yes 25 (75.8)
Radical resection
Lobectomy 23 (69.7)
Pneumonectomy 10 (30.3)
pT stage
T1 3 (9.1)
T2 16 (48.5)
T3 7 (21.2)
T4 7 (21.2)
pN stage
N0 1 (3.0)
N1 5 (15.2)
N2 24 (72.7)
N3 3 (9.1)
pStage
IIIa 23 (69.7)
IIIb 10 (30.3)
Grade
MD 15 (45.5)
PD 18 (54.5)
Resection margin
Negative 21 (63.6)
Closed 1 (3.0)
Positive 11 (33.3)
Lymphovascular invasion
No 26 (78.8)
Yes 7 (21.2)
Perineural invasion
No 30 (90.9)
Yes 3 (9.1)
Extranodal extension
No 29 (87.9)
Yes 4 (12.1)
SOX2 gene amplification
None 11 (33.3)
Low 18 (54.5)
High 4 (12.2)
SOX2 protein expression
Weak 7 (21.2)
Moderate 18 (54.5)
Strong 8 (24.3)
Table 1. Continued
Variable No. (%)
Postoperative chemotherapy
No 4 (12.2)
Yes 29 (87.8)
Total dose, median (range, Gy) 59.4 (50.4-69)
Fraction size, median (range, Gy) 1.8 (1.8-2)
ECOG, Eastern Cooperative Oncology Group; MD, mod-
erately differentiated; PD, poorly differentiated.
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Table 2. Relationship between SOX2 gene amplification and SOX2 protein expression
Table 3. Clinicopathologic characteristics according to SOX2 amplification and expression
Variable SOX2 gene amplification SOX2 protein expression
None (n=11) Amplification (n=22) p-value No (n=7) Overexpression (n=26) p-value
Sex
Male 10 (90.9) 22 (100) 0.33 6 (85.7) 26 (100) 0.2
Female 1 (9.1) 0 (0.0) 1 (14.3) 0 (0.0)
Age (yr)
< 65 7 (63.6) 8 (36.4) 0.14 4 (57.1) 11 (42.3) 0.67
! 65 4 (36.4) 14 (63.6) 3 (42.9) 15 (57.7)
Smoking history
No 4 (36.4) 4 (18.2) 0.39 3 (42.9) 5 (19.2) 0.32
Yes 7 (63.6) 18 (81.8) 4 (57.1) 21 (80.8)
Tumor size (cm)
< 4 4 (36.4) 9 (40.9) 1 1 (14.3) 12 (46.2) 0.2
! 4 7 (63.6) 13 (59.1) 6 (85.7) 14 (53.8)
Differentiation
MD 5 (45.5) 10 (45.5) 1 4 (57.1) 11 (42.3) 0.67
PD 6 (54.5) 12 (54.5) 3 (42.9) 15 (57.7)
TNM stage
IIIa 9 (81.8) 14 (63.6) 0.43 6 (85.7) 17 (65.4) 0.4
IIIb 2 (18.2) 8 (36.4) 1 (14.3) 9 (34.6)
T stage
T1-2 6 (54.5) 13 (59.1) 1 3 (42.9) 16 (61.5) 0.42
T3-4 5 (45.5) 9 (40.9) 4 (57.1) 10 (38.5)
N stage
N0-1 3 (27.3) 3 (13.6) 0.38 2 (28.6) 4 (15.4) 0.58
N2-3 8 (72.7) 19 (86.4) 5 (71.4) 22 (84.6)
Resection margin
Negative 7 (63.6) 14 (63.6) 1 5 (71.4) 16 (61.5) 1
Closed or positive 4 (36.4) 8 (36.4) 2 (28.6) 10 (38.5)
Lymphovascular invasion
No 8 (72.7) 18 (81.8) 0.66 5 (71.4) 21 (80.8) 0.62
Yes 3 (27.3) 4 (18.2) 2 (28.6) 5 (19.2)
Perineural invasion
No 11 (100) 19 (86.4) 0.53 7 (100) 23 (88.5) 1
Yes 0 (0.0) 3 (13.6) 0 (0.0) 3 (11.5)
Extranodal extension
No 10 (90.9) 19 (86.4) 1 6 (85.7) 23 (88.5) 1
Yes 1 (9.1) 3 (13.6) 1 (14.3) 3 (11.5)
Values are presented as number (%). MD, moderately differentiated; PD, poorly differentiated.
SOX2 protein expression SOX2 gene amplification p-value
No Yes
No expression 6 (54.5) 1 (4.5) 0.002
Overexpression 5 (45.5) 21 (95.5)
Values are presented as number (%).
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patients who underwent radiotherapy in NSCLC, albeit only
a small number of patients were included. Nevertheless, 
despite the high possibility, we cannot assume that postop-
erative radiotherapy changed the prognosis of patients and
that SOX2 is involved in this effect. We were also unable to
confirm a relationship between SOX2 and radioresistance.
Thus, further studies are certainly needed in order to validate
the effect of postoperative radiotherapy on prognosis and the
relationship between radiotherapy and SOX2. Still, based on
our findings, it is meaningful that the prognostic value of
SOX2 overexpression was verified by utilizing the homoge-
nous database of all patients treated with the whole defini-
tive treatment scheme including radical surgery followed by
postoperative radiotherapy.
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Fig. 2. Kaplan-Meier curves for overall survival and disease-free survival rates. (A) Patients with SOX2 overexpression
showed a significantly longer overall survival rate compared to those without (median, 73 months vs. 8 months, respectively;
p=0.01). (B) Patients with SOX2 amplification did not show a better overall survival rate than those without amplification
(median, 69 months vs. 59 months; p=0.95). (C) Patients with SOX2 overexpression showed a significant trend toward longer
disease-free survival compared to those without (median, 57 months vs. 5 months; p=0.08). (D) Patients with SOX2 ampli-
fication did not show a longer disease-free survival than those without amplification (median, 30 months vs. 82 months;
p=0.48).
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This study has several shortcomings. Primarily, it was ret-
rospective in design and included only a small number of 
patients who underwent postoperative radiotherapy. We
thought that SOX2 overexpression showed a significant
trend toward better DFS on the Kaplan-Meier curve in 
Fig. 2C due to the small number of patients in spite of signif-
icant relationship between SOX2 overexpression and pro-
gression-free survival in multivariate analysis. A well-
designed large-scale prospective study is necessary to con-
firm our results. In addition, despite a very strong positive
relationship between SOX2 protein overexpression and gene
amplification, gene amplification of SOX2 did not show sig-
nificant association with OS or DFS, in contrast to SOX2 over-
expression. Similarly, in a recent large retrospective study,
only SOX2 overexpression showed significant association
with better overall survival, although significant positive cor-
relation was observed between SOX2 protein overexpression
and gene amplification [8]. Furthermore, from an indepth 
review of our data, five patients with SOX2 overexpression
without gene amplification showed an excellent outcome of
median OS (60 months). Based on these findings, we suggest
that a high SOX2 protein level may affect the prognosis of
lung squamous cell carcinoma patients more acutely than
SOX2 gene amplification. Consequently, we recommend an
evaluation of the mechanism of SOX2 overexpression with
no gene amplification. Thus, further studies investigating
other mechanisms of SOX2 protein overexpression, such as
chromosomal translocation or mutation without gene ampli-
fication, would also be necessary.
Conclusion
In conclusion, SOX2 overexpression could be a positive
prognostic factor in lung squamous cell carcinoma patients
treated with postoperative adjuvant radiotherapy. Further
Table 4. Stepwise uni- and multi-variate analysis using Cox regression model for overall survival and disease-free survival
Overall survival Disease-free survival
Variable Univariable Multivariable Univariable Multivariable
Median p-value HR p-value Median p-value HR p-value(mo) (95% CI) (mo) (95% CI)
Age 96 vs. 59 0.05 0.33 (0.11-0.98) 0.046 96 vs. 12 0.02 - -
(< 65 yr vs. ! 65 yr)
Tumor size 73 vs. 18 0.16 - - 59 vs. 10 0.14 - -
(< 4 cm vs. ! 4 cm)
Differentiation 69 vs. 59 0.65 - - 69 vs. 30 0.76 - -
(MD vs. PD)
T stage (T1-2 vs. T3-4) 96 vs. 57 0.26 - - 69 vs. 30 0.29 - -
N stage (N0-1 vs. N2-3) 59 vs. 69 0.99 - - 31 vs. 57 0.85 - -
Resection margin 69 vs. 59 0.91 - - 69 vs. 30 0.49 - -
(negative vs. closed 
or positive)
Lymphovascular invasion 69 vs. 59 0.72 - - 30 vs. 59 0.48 - -
(no vs. yes)
Perineural invasion 59 vs. NR 0.13 - - 31 vs. NR 0.12 - -
(no vs. yes)
Extranodal extension 69 vs. 59 0.9 - - 31 vs. 30 0.9 - -
(no vs. yes)
Total dose 96 vs. 59 0.09 - - 96 vs. 30 0.04 0.13 (0.02-0.7) 0.02
(> 59.4 Gy vs. # 59.4 Gy)
SOX2 gene amplification 69 vs. 59 0.95 - - 30 vs. 82 0.48 - -
(yes vs. no)
SOX2 overexpression 73 vs. 8 0.01 0.1 (0.02-0.5) 0.005 57 vs. 5 0.08 0.15 (0.04-0.65) 0.01
(yes vs. no)
HR, hazard ratio; CI, confidence interval; MD, moderately differentiated; PD, poorly differentiated; NR, not reached.
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